Cargando…

Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab

BACKGROUND: Doppler ultrasound imaging is useful for management of venous thromboembolism associated with a subclavicular implantable central venous access system in patients receiving bevacizumab (Bev). We investigated the efficacy and safety of our anticoagulant regimen based on Doppler findings....

Descripción completa

Detalles Bibliográficos
Autores principales:	Suenaga, Mitsukuni, Mizunuma, Nobuyuki, Shinozaki, Eiji, Matsusaka, Satoshi, Ozaka, Masato, Ogura, Mariko, Chin, Keisho, Yamaguchi, Toshiharu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315555/ https://www.ncbi.nlm.nih.gov/pubmed/25670906 http://dx.doi.org/10.2147/OTT.S75722

Ejemplares similares

A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?
por: Osumi, Hiroki, et al.
Publicado: (2015)

Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer
por: Ohhara, Yoshihito, et al.
Publicado: (2015)

Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients
por: Nakayama, Izuma, et al.
Publicado: (2017)

Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients
por: Sato, Yasuyoshi, et al.
Publicado: (2015)

Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab
por: Ushida, Yuta, et al.
Publicado: (2018)

Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01)
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab
por: Osumi, Hiroki, et al.
Publicado: (2015)

Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report
por: Osumi, Hiroki, et al.
Publicado: (2013)

Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel
por: Fukuda, Naoki, et al.
Publicado: (2018)

Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer
por: Suenaga, Mitsukuni, et al.
Publicado: (2016)

Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research
por: Takahari, Daisuke, et al.
Publicado: (2020)

Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study
por: Kitagawa, Yusuke, et al.
Publicado: (2020)

Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy
por: Matsusaka, Satoshi, et al.
Publicado: (2016)

Treatment features of systemic chemotherapy in young adults with unresectable advanced or recurrent gastric cancer
por: Nakayama, Izuma, et al.
Publicado: (2018)

Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab
por: Kamiimabeppu, Daisaku, et al.
Publicado: (2021)

Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan: a novel colorectal cancer marker
por: Shinozaki, Eiji, et al.
Publicado: (2018)

Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2018)

Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake
por: Osumi, Hiroki, et al.
Publicado: (2018)

Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting
por: Nakayama, Izuma, et al.
Publicado: (2020)

Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study
por: Kitagawa, Yusuke, et al.
Publicado: (2019)

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
por: Wakatsuki, Takeru, et al.
Publicado: (2018)

Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer
por: Yagi, Shusuke, et al.
Publicado: (2018)

Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Sex Differences in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism
por: Blanco-Molina, Angeles, et al.
Publicado: (2014)

Change in clinical outcomes during the transition of adjuvant chemotherapy for stage III colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2017)

Patients’ self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis
por: Kawakami, Kazuyoshi, et al.
Publicado: (2015)

New anticoagulants for the prevention of venous thromboembolism
por: Becattini, Cecilia, et al.
Publicado: (2010)

New anticoagulants for the treatment of venous thromboembolism
por: Fernandes, Caio Julio Cesar dos Santos, et al.
Publicado: (2016)

Extended anticoagulation for unprovoked venous thromboembolism
por: Castellucci, Lana A., et al.
Publicado: (2018)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Direct oral anticoagulants and venous thromboembolism
por: Franchini, Massimo, et al.
Publicado: (2016)

Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism
por: Farge, Dominique, et al.
Publicado: (2015)

Venous Thromboembolism in Hospitalized Patients With COVID-19 Receiving Prophylactic Anticoagulation
por: Boonyasai, Romsai T., et al.
Publicado: (2020)

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism
por: McRae, Simon J, et al.
Publicado: (2005)

Optimal duration of anticoagulation in patients with venous thromboembolism
por: Prandoni, Paolo, et al.
Publicado: (2011)

Acute on Chronic Venous Thromboembolism on Therapeutic Anticoagulation
por: Bassi, Byron, et al.
Publicado: (2013)

Pharmacology of anticoagulants used in the treatment of venous thromboembolism
por: Nutescu, Edith A., et al.
Publicado: (2016)

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism
por: Kim, Joo Hee, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bo4p1jv2igiu3vdabosrdta3ru